The research team, led by Ayami Koike and colleagues in the Department of Gynecology and Obstetrics, enrolled 153 patients newly diagnosed with gynecologic malignancies between July 2022 and March 2026. After accounting for withdrawals and incomplete data, 105 patients formed the analytical cohort. Each participant completed a brief validated self-administered diet history questionnaire capturing dietary habits over the preceding month, once at baseline before treatment began and again one day before the third chemotherapy cycle. Appetite and quality of life were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, known as the EORTC QLQ-C30, while treatment-related symptoms were tracked using the patient-reported version of the Common Terminology Criteria for Adverse Events, or PRO-CTCAE.

The headline result was stark. Forty-one of the 105 patients, or 39.0 percent, reported appetite loss before their third chemotherapy cycle. Compared with patients who maintained their appetite, this group experienced a median additional reduction in daily energy intake of 320.8 kilocalories, with a 95 percent confidence interval stretching from 454.5 down to 119.3 kilocalories per day. The decline was not confined to total calories. Protein intake fell by a median of 12.0 grams per day, fat by 8.3 grams, and carbohydrate by 25.6 grams more in the appetite loss group, each difference statistically significant. Crucially, the proportion of energy derived from protein, fat, and carbohydrate, the so-called PFC ratio, did not differ between the groups, indicating that appetite loss shrinks the entire diet roughly proportionally rather than skewing it toward any particular macronutrient.

The micronutrient analysis added a layer of nuance. Of the 16 clinically relevant micronutrients examined, 13 showed significantly larger decreases in the appetite loss group after correction for multiple comparisons using the Benjamini-Hochberg false discovery rate procedure. Iron, zinc, magnesium, and vitamin B2 displayed the largest effect sizes, with Hedges’ g values ranging from minus 0.68 to minus 0.76, while the remaining nine nutrients showed small to moderate effects. Yet when the researchers adjusted for total energy intake by expressing micronutrient consumption as nutrient density per 1,000 kilocalories, none of the between-group differences remained significant. In other words, the diet of patients with appetite loss appears to shrink uniformly, preserving its nutritional composition in relative terms even as absolute intakes of vitamins and minerals fall in ways that could matter for patients facing prolonged energy restriction.

At the level of individual food groups, a telling pattern emerged. Patients with appetite loss showed a significantly greater decline in red and processed meat consumption, with a median difference of minus 6.1 grams per day, while dairy products and legumes also trended downward. Poultry, fish, vegetables, fruits, sweets, and staple carbohydrate sources such as rice and other grains showed no meaningful differences between groups. This selective retreat from meat is consistent with a growing body of literature identifying meat as the most commonly aversive food during anticancer treatment, and with studies linking impaired taste function to reduced preference for protein-rich foods. The researchers suggest that altered food preferences during chemotherapy, rather than a uniform distaste for all foods, may be shaping what patients can and cannot bring themselves to eat.

When the team probed which treatment side effects were most closely tied to appetite loss, one stood out above the rest. In multivariable linear regression models adjusted for age and body mass index, taste changes were significantly associated with appetite loss scores, carrying a beta coefficient of 8.7 with a 95 percent confidence interval of 1.3 to 16.1 and a p value of 0.02. Fatigue, constipation, nausea, mouth sores, diarrhea, and dry mouth all failed to reach significance. The finding carries a provocative implication: the distortion of taste that many patients describe during chemotherapy may be a principal driver of the anorexia that follows, rather than nausea or gastrointestinal distress as is often assumed.

The connection to quality of life was equally compelling. Changes in appetite loss scores were negatively correlated with changes in global health status and quality of life, with a Spearman correlation coefficient of minus 0.31 and a p value of 0.002. The associations were strongest for role functioning, cognitive functioning, social functioning, and emotional functioning, with correlation coefficients of minus 0.49, minus 0.42, minus 0.35, and minus 0.28 respectively, and weakest for physical functioning, which did not reach statistical significance. This gradient suggests that appetite loss may weigh more heavily on psychological and social well-being than on the body’s mechanical capacity, a pattern consistent with prior research linking poor food intake to depressive symptoms and diminished quality of life in cancer populations.

To test whether appetite loss tracks with quality of life fluctuations over time, the investigators turned to a separate multicenter cohort of 127 patients with gynecologic malignancies treated at five Japanese institutions between June 2020 and March 2024. Patient-reported outcomes were collected longitudinally over a 15-week observation period, revealing that global quality of life scores fluctuate within each chemotherapy cycle, dipping in the first week after treatment and recovering by the second. Machine learning models built to identify which symptom changes best predicted clinically meaningful quality of life shifts, defined as a change of at least 10 points on the EORTC QLQ-C30 global score, consistently ranked appetite loss among the most influential features, with model interpretation performed using Shapley additive explanations. The implication is sobering: some of the most clinically relevant swings in a patient’s well-being may occur between hospital visits, precisely when clinicians are least able to observe them.

Notably, appetite loss did not translate into the objective nutritional markers clinicians often rely upon. The proportion of patients losing more than 5 percent of body weight was similar between groups, at 26.8 percent versus 21.9 percent, and serum albumin levels and the Prognostic Nutritional Index, a composite of albumin and lymphocyte count, showed no significant differences. This dissociation between subjective dietary collapse and stable laboratory parameters suggests that conventional biochemical surveillance may miss the early, patient-centered harm caused by appetite loss, and that patient-reported measures deserve a more central role in monitoring. Nutritional counseling, it is worth noting, was provided to only 7.6 percent of patients, with no significant difference between groups.

The authors are careful about causality. Appetite was assessed over the preceding week while diet questionnaires covered the preceding month, so the temporal direction of the association cannot be established, and the definition of appetite loss included mild symptoms that may not generalize to severe anorexia. Selection bias cannot be excluded, serum zinc was not measured, and residual confounding by postoperative recovery remains possible, since most patients received adjuvant chemotherapy after surgery. Sensitivity analyses, however, strengthened the core findings: restricting the analysis to patients without baseline appetite loss, adjusting for surgical approach and the interval from surgery to chemotherapy, and grading appetite loss severity all produced directionally consistent results. The clinical message is clear. Because appetite loss and taste alterations are common, detectable, and plausibly treatable, whether through dietary counseling tailored to taste changes, oral nutritional supplements, or emerging pharmacological options such as olanzapine and mirtazapine that have improved both appetite and quality of life in cancer trials, systematic screening with electronic patient-reported outcome tools could catch the problem before it erodes a patient’s nutrition and spirit mid-treatment.

Subject of Research: Appetite loss, dietary intake, and quality of life during chemotherapy for gynecologic cancer

Article Title: Appetite loss during chemotherapy is associated with reduced dietary intake and quality of life in patients with gynecologic cancer: a prospective observational study

Article References: Koike, A., Mizuno, R., Higashiyama, N., Inayama, Y., Umemiya, M., Ikeda, K., Kubo, N., Tokushige, Y., Nagasawa, T., Matsumura, N., Miyamoto, T., Taki, M., Yamanoi, K., Murakami, R., Yamaguchi, K., & Mandai, M. (2026). Appetite loss during chemotherapy is associated with reduced dietary intake and quality of life in patients with gynecologic cancer: a prospective observational study. Supportive Care in Cancer, 34(10), Article 1046. https://doi.org/10.1007/s00520-026-11276-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11276-8

Keywords: gynecologic cancer, chemotherapy, appetite loss, dietary intake, quality of life, taste changes, micronutrients, EORTC QLQ-C30, PRO-CTCAE, supportive care, nutrition, patient-reported outcomes